RT Journal Article SR Electronic T1 International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature JF Pharmacological Reviews JO Pharmacol Rev FD American Society for Pharmacology and Experimental Therapeutics SP 579 OP 587 DO 10.1124/pr.110.003111 VO 62 IS 4 A1 Jerold Chun A1 Timothy Hla A1 Kevin R. Lynch A1 Sarah Spiegel A1 Wouter H. Moolenaar YR 2010 UL http://pharmrev.aspetjournals.org/content/62/4/579.abstract AB Lysophospholipids are cell membrane-derived lipids that include both glycerophospholipids such as lysophosphatidic acid (LPA) and sphingoid lipids such as sphingosine 1-phosphate (S1P). These and related molecules can function in vertebrates as extracellular signals by binding and activating G protein-coupled receptors. There are currently five LPA receptors, along with a proposed sixth (LPA1-LPA6), and five S1P receptors (S1P1-S1P5). A remarkably diverse biology and pathophysiology has emerged since the last review, driven by cloned receptors and targeted gene deletion (“knockout”) studies in mice, which implicate receptor-mediated lysophospholipid signaling in most organ systems and multiple disease processes. The entry of various lysophospholipid receptor modulatory compounds into humans through clinical trials is ongoing and may lead to new medicines that are based on this signaling system. This review incorporates IUPHAR Nomenclature Committee guidelines in updating the nomenclature for lysophospholipid receptors (http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=36).